161 related articles for article (PubMed ID: 27374686)
1. Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.
Shima T; Kamezaki K; Higashioka K; Takashima S; Yoshimoto G; Kato K; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Akashi K
Intern Med; 2016; 55(13):1793-6. PubMed ID: 27374686
[TBL] [Abstract][Full Text] [Related]
2. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
[TBL] [Abstract][Full Text] [Related]
3. A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.
Sekiguchi Y; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Kinoshita A; Suga Y; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(9):6278-90. PubMed ID: 25337281
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J
Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
[TBL] [Abstract][Full Text] [Related]
6. [Long-term remission with mogamulizumab monotherapy in a patient with refractory adult T-cell leukemia-lymphoma].
Nakaya Y; Tsutsumi M; Fuseya H; Horiuchi M; Yoshimura T; Hayashi Y; Kanashima H; Nakao T; Yamane T
Rinsho Ketsueki; 2018; 59(3):326-328. PubMed ID: 29618693
[TBL] [Abstract][Full Text] [Related]
7. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
8. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
9. [Adult T-cell leukemia-lymphoma complicated by Takotsubo cardiomyopathy and HTLV-1-associated myelopathy after treatment with the anti-CCR4 antibody mogamulizumab].
Yamanaka S; Nakayama K; Tamai H; Sakamaki M; Inokuchi K
Rinsho Ketsueki; 2017; 58(4):309-314. PubMed ID: 28484158
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
11. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
Ishitsuka K; Yurimoto S; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
Eur J Haematol; 2019 May; 102(5):407-415. PubMed ID: 30740787
[TBL] [Abstract][Full Text] [Related]
13. Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study.
Maemoto H; Ariga T; Kusada T; Heianna J; Manabe Y; Miyakawa A; Nakachi S; Morishima S; Iraha S; Ganaha F; Masuzaki H; Murayama S
Jpn J Clin Oncol; 2019 Feb; 49(2):153-159. PubMed ID: 30452692
[TBL] [Abstract][Full Text] [Related]
14. Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia-lymphoma treated with mogamulizumab.
Tamaki K; Kinjo T; Aoyama H; Tomoyose T; Nakachi S; Hanashiro T; Shimabukuro N; Tedokon I; Morichika K; Nishi Y; Taira N; Fujita J; Yoshimi N; Fukushima T; Masuzaki H
J Infect Chemother; 2015 Nov; 21(11):820-3. PubMed ID: 26231316
[TBL] [Abstract][Full Text] [Related]
15. Unilateral conjunctival infiltration of Adult T-cell leukemia/lymphoma. Case report and literature review.
Shimono J; Kaino S; Okada K; Oshimi K; Ishida Y; Takahashi T; Miyagishima T; Teshima T
J Clin Exp Hematop; 2017; 57(3):143-146. PubMed ID: 29279551
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
Motohashi K; Suzuki T; Kishimoto K; Numata A; Nakajima Y; Tachibana T; Ohshima R; Kuwabara H; Tanaka M; Tomita N; Ishigatsubo Y; Fujisawa S
Int J Hematol; 2013 Aug; 98(2):258-60. PubMed ID: 23801427
[TBL] [Abstract][Full Text] [Related]
17. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
19. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
Iida S; Ishida T; Ueda R
Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
[TBL] [Abstract][Full Text] [Related]
20. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
